Arix Bioscience acquires 11% stake in Phamaxis Ltd.
An investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1116 entries already.
Entries by Thomas Gabrielczyk
Morphosys launches US subsidiary, appoints lead
/in News/by Thomas GabrielczykMorphosys has named Jennifer Herron President of MorphoSys US Inc. to build up sales presence overseas.
Narasimhan embraces Swiss biotech industry
/in News/by Thomas GabrielczykVas Narasimhan, the newly appointed CEO of Swiss pharma giant Novartis, introduced himself to the Swiss biotech industry with a stimulant talk at the Swiss Biotech Day. Apart from that […]
Business as usual in Amsterdam
/in News/by Thomas GabrielczykThe tremendous success of last years BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised […]
Global Bioenergies delivers first batch of cosmetics ingredient
/in News/by Thomas GabrielczykFrench green chemistry specialist Global Bioenergies announced the delivery of a first batch of sustainable cosmetic ingredients to cosmetics heavyweight L’Oréal. It was produced as part of the ISOPROD project, […]
BIO-Europe more popular than ever
/in News/by Thomas GabrielczykMore than 4,000 participants from all over the globe visited Berlin in early November to take part in this years BIO-Europe. The event continues to be on the upswing […]
300 jobs more: US company expands its Irish campus
/in News/by Thomas GabrielczykUS biotech company Regeneron Pharmaceuticals revealed plans to create some 300 new jobs in Ireland’s Limerick County. The jobs form part of a US$100m (85m) expansion plan for the company’s […]
Immunethep receives grant from Gates Foundation
/in News/by Thomas GabrielczykPortuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH.
Uniqure readies share stock offering
/in News/by Thomas GabrielczykDutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares.
Voluntary health agency jump-starts Selvitas SEL120 programme
/in News/by Thomas GabrielczykThe Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients […]